Topical Cream for Chemo Neuropathy: Early Trial, Big Caveats

A cream designed to quiet pain-sensing nerve endings before chemotherapy irritates them reduced chemotherapy-induced peripheral neuropathy (CIPN) in patients' hands in one pilot randomized trial. Hand CIPN occurred in 13% of participants using the experimental cream and 32% using a moisturizer control: a 19-percentage-point absolute difference and roughly a 59% relative reduction (p=0.03). That is an intriguing result in a field with no established preventive treatment. It is also one small, sponsor-linked study of a product that is not available to patients.

The idea deserves attention because it starts in a different place. Most attempted CIPN preventives have aimed to protect nerves through supplements, intravenous drugs, or systemic neuroprotectants. This formulation was intended to act at the skin's sensory nerve endings, where chemotherapy may first amplify abnormal signaling. Whether that local strategy can prevent the broader syndrome remains unknown.

Why preventing CIPN matters

Taxane and platinum chemotherapies can cause numbness, tingling, pain, altered temperature sensation, weakness, and loss of dexterity. CIPN can limit chemotherapy dosing and may persist after treatment. The PATTERN observational study protocol describes the downstream stakes: persistent symptoms can contribute to gait changes, falls, impaired physical function, and lower quality of life.

Clinicians can treat established symptoms, but prevention has resisted decades of effort. The 2024 Kleckner et al. exercise pilot notes more than 20 years of research and over 100 clinical trials without a validated preventive standard of care. The concept document identifies duloxetine, gabapentin, and high-dose capsaicin patches as options used for existing symptoms, not proven prophylaxis. A preventive that worked reliably could therefore matter far more than a pleasant hand cream usually gets to matter.

The trial tested prevention in hands, not feet

In the 2026 Servitja et al. pilot randomized clinical study, 142 people receiving neurotoxic chemotherapy at nine Spanish hospitals were assigned to Oncapsisens® or an identical-appearing moisturizer control. Oncapsisens contains Calmapsin®, a synthetic "soft vanilloid." Participants applied their assigned product daily to their hands from the start of chemotherapy.

The study assessed CIPN with CTCAE v5.0 and the Leonard Scale, both patient-reported outcome measures. For the hands, CIPN incidence was 13% in the experimental-cream group and 32% in the control group (p=0.03). The publication reports no confidence interval for this comparison in the evidence summarized here, so the precision of the estimate cannot be judged from a confidence interval. Still, the reported p value meets the study's threshold for statistical significance.

The feet result was different: CIPN incidence was 67% with the nociceutical cream and 73% with control (p=0.1). This difference was not statistically significant. Crucially, participants did not use the cream on their feet prophylactically. They began foot application only after sensory symptoms emerged. The hand and foot findings therefore do not test the same intervention at the same point in disease development. The study cannot show whether daily preventive application to the feet would work, and the foot result cannot establish that the cream fails there.

The formulation-related adverse event reported was mild grade 1 itching in four participants, two in each group. That small count does not establish long-term safety, but the trial did not identify an obvious short-term safety imbalance.

A plausible mechanism is not proof of nerve protection

Calmapsin was engineered to modulate several ion channels involved in sensory signaling: TRPV1, TRPM8, TRPA1, and voltage-gated sodium channels. The proposed advantage is an ester group designed to be hydrolyzed within the dermis, limiting systemic absorption. In theory, applying such a compound before chemotherapy activates epidermal nociceptive terminals could interrupt an early stage of pain signaling without exposing the rest of the body to a neuroprotective drug.

Topical modulation of nociceptors has biological precedent, though not proof for this use. In a randomized trial in people with spinal-cord-injury focal neuropathic pain, an 8% capsaicin patch produced clinically meaningful pain relief. Capsaicin is pungent, works through intense TRPV1 agonism and desensitization, and treats established pain; it is not Calmapsin, and it was not tested as CIPN prevention.

The distinction matters. The Oncapsisens study measured symptoms, not nerve structure or function directly. It did not include intraepidermal nerve fiber density from skin biopsies, quantitative sensory testing, or nerve-conduction measures. Less reported neuropathy could reflect protected nerve fibers, altered symptom perception, or both. Patient-reported symptoms are clinically meaningful, but they cannot by themselves prove the proposed anatomical mechanism.

Why this signal needs replication

Pilot trials commonly produce larger effects than later, larger trials. This study was powered for a large effect size (Cohen's d=0.60), and the 19-point hand difference could shrink substantially in a confirmatory study. The authors describe their work as a pilot and call for replication.

Several design features add uncertainty. The trial was registered in November 2024 relative to its study timeline, raising a transparency concern about whether endpoints and analysis plans were fully specified before results were known. Identical tubes help preserve blinding, but a compound that changes thermal or tactile sensation could still reveal allocation to participants. That matters when the endpoints are symptom reports. The formulation's developer sponsored the work and supplied the product, while no independent replication exists.

The field's history should also temper excitement. A 2023 review of antioxidants for CIPN describes a familiar pattern: alpha-lipoic acid, acetyl-L-carnitine, vitamin E, and other candidates often looked promising before failing to establish Phase III efficacy or raising safety concerns. A fresh mechanism does not erase that prior record.

CIPN has more than one address

A skin-level intervention may target an important early site of injury without addressing every mechanism that produces CIPN. Taxane, platinum, and other chemotherapy-related neuropathies can involve distal nerve endings, dorsal root ganglia, inflammatory signaling, and possibly central mechanisms. In a 2021 longitudinal study of 116 sedentary women receiving taxane- or platinum-based chemotherapy for breast cancer, Kleckner et al. found that pre-chemotherapy inflammatory markers and other clinical, behavioral, and psychosocial factors helped predict symptom severity after six weeks. That association does not identify a single cause, but it argues against a one-switch explanation.

Preclinical work points in the same direction. A 2025 fucoidan study reported that the compound reduced neuropathy in experimental models through a gut-blood-dorsal-root-ganglion inflammatory pathway. The result does not test Oncapsisens and does not establish a human treatment, but it illustrates why a topical product may have a ceiling: it cannot directly reach systemic inflammatory pathways or dorsal root ganglia.

Other non-systemic approaches remain investigational. A 2024 systematic review of non-pharmacological approaches in women treated for breast cancer found variable and generally insufficient evidence for options such as cryotherapy, compression, exercise, and acupuncture. Exercise rehabilitation can improve function and quality of life in cancer survivors; a meta-analysis of 19 randomized trials involving 2,974 participants found benefits could persist for six to 12 months. But that is evidence for rehabilitation outcomes, not proof that exercise prevents CIPN.

What patients can do now

Oncapsisens and Calmapsin are not commercially available. No over-the-counter cream has been shown to reproduce this formulation's multi-channel, locally hydrolyzed design. Low-dose capsaicin creams and capsaicin supplements are not substitutes for this intervention, and the available capsaicin evidence concerns treatment rather than prevention.

For people receiving neurotoxic chemotherapy, the practical response remains clinical: report numbness, tingling, pain, balance trouble, or loss of hand function early; discuss dose modification when symptoms become severe; and ask the oncology team about treatment for established symptoms and rehabilitation to maintain function. Remote symptom tracking may help identify changes between visits, as explored in a 2025 observational study of app-based CIPN monitoring, but monitoring is not prevention.

The hand result is a credible proof of concept, not a product recommendation. A larger independently conducted trial with prespecified analyses, consistent preventive application to hands and feet, and objective nerve measures would show whether topical nociceptor targeting can deliver a clinically durable benefit.

Until then, the finding moves topical prevention from "interesting hypothesis" to "worth testing properly." It does not yet change care.